Rein Therapeutics (RNTX) Assets Average (2017 - 2025)
Rein Therapeutics (RNTX) has disclosed Assets Average for 9 consecutive years, with $38.9 million as the latest value for Q4 2025.
- Quarterly Assets Average fell 53.21% to $38.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.9 million through Dec 2025, down 53.21% year-over-year, with the annual reading at $43.2 million for FY2025, 48.66% down from the prior year.
- Assets Average for Q4 2025 was $38.9 million at Rein Therapeutics, down from $55.6 million in the prior quarter.
- The five-year high for Assets Average was $106.8 million in Q3 2024, with the low at $13.4 million in Q3 2023.
- Average Assets Average over 5 years is $53.3 million, with a median of $53.6 million recorded in 2021.
- The sharpest move saw Assets Average crashed 57.92% in 2023, then surged 696.69% in 2024.
- Over 5 years, Assets Average stood at $51.6 million in 2021, then crashed by 52.31% to $24.6 million in 2022, then soared by 141.33% to $59.4 million in 2023, then skyrocketed by 40.04% to $83.2 million in 2024, then crashed by 53.21% to $38.9 million in 2025.
- According to Business Quant data, Assets Average over the past three periods came in at $38.9 million, $55.6 million, and $57.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.